NCT04149899View on ClinicalTrials.gov

Safety and IOP-Lowering Effects of WB007

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

November 14, 2019

Primary Completion Date

January 31, 2021

Study Completion Date

December 14, 2022

Conditions
Glaucoma, Primary Open AngleOcular Hypertension
Interventions
DRUG

WB007 0.05%

WB007 Ophthalmic Solution 0.05%

DRUG

WB007 0.15%

WB007 Ophthalmic Solution 0.15%

DRUG

WB007 0.4%

WB007 Ophthalmic Solution 0.4%

DRUG

Timolol 0.5%

Timolol Maleate 0.5% Ophthalmic Solution

Trial Locations (1)

92663

Eye Research Foundation, Newport Beach

All Listed Sponsors
lead

Bausch & Lomb Incorporated

INDUSTRY

NCT04149899 - Safety and IOP-Lowering Effects of WB007 | Biotech Hunter | Biotech Hunter